A new poll of adults over age 50 – one of the highest-priority groups to receive a COVID-19 vaccine – suggests an uphill climb may lie ahead for some in this group to get vaccinated.
One in five older adults (20%) indicated they want to get a COVID-19 vaccine as soon as possible. However, nearly half (46%) said they want to wait until others have received it, according to the survey released Nov. 24 by the National Poll on Healthy Aging project at University of Michigan. Continue reading
Photo: NIAID via FlickrTransmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient.
There’s good news for older adults from a new phase2/phase 3 trial of the COVID-19 vaccine under development by Oxford University and AstraZeneca. Researchers found that the partners’ ChAdOx1 nCoV-19 vaccine provides a similar immune response across age groups following a boost dose and appears to be better tolerated in older adults than in younger adults, according to a study published last week in The Lancet. Continue reading
Hilary Marston, M.D., medical officer and policy adviser for pandemic preparedness at the National Institute of Allergy and Infectious Diseases, said she and her colleagues are “thrilled” about announcements that at least two COVID-19 vaccines so far have been shown to have an efficacy of over 90% in late-stage clinical trials.
“I don’t think any of us could have hoped for those results,” Marston said during a Nov. 18 interview at the AHCJ Journalism Summit on Infectious Disease. “We are … ready to work with the FDA to get the data to them as soon as possible.” Continue reading
Francis S. Collins
As coronavirus infections rise nationwide, health care journalists have an important role in explaining the science behind the development, safety and effectiveness of COVID-19 vaccines, said Francis S. Collins, M.D., Ph.D., the director of the National Institutes of Health.
As the Nov. 18 keynote speaker at AHCJ’s Journalism Summit on Infectious Disease, Collins gave a stark warning for journalists and all Americans about the need to recognize the value of the vaccines as they are rolled out in the coming months. Continue reading
In a previous blog post, I discussed what reporters look for when they dig into the data from the various COVID-19 vaccine clinical trials. That post covered the do’s, but it didn’t cover the red flags that reporters should watch for as well.
Vinay Prasad, M.D., a hematologist-oncologist and associate professor of medicine at the University of California, San Francisco, followed up his Twitter thread on what to look for with a list of common problems in vaccine clinical trials that journalists also should monitor: Continue reading
Until 2020, many Americans (except health reporters) tended to consider influenza as just a nuisance winter illness that might keep one in bed for a few days. However, this year, with COVID-19 still roiling the country, the flu needs to be considered more seriously.
Adding to concerns are polls showing that people may be reluctant to get a flu shot, which may influence others to hold off. CNN reports that one in three parents said they had no plan to go to their doctor’s office and vaccinate their kids, even though more than 100 children die of the flu each year. Most of the children that die from the flu didn’t get a flu shot. Continue reading